::: Transgene signs an exclusive option agreement for the development and commercialisation of its immunotherapy product TG4010
agreement Transgene, Phase IIb/III development of TG4010, pay Transgene, commercialisation of Transgene, Transgene signs, clinical development phase of TG4010, exclusive option agreement, immunotherapy product TG4010, TG4010 expresses

::: Cellzome Announces Second Major Strategic Drug Discovery Alliance with GlaxoSmithKline in Inflammatory Disease
Collaboration exploits Cellzome, inflammatory bowel disease, treat inflammatory disease, world-leading proteomics technology, treatment of inflammatory diseases, new technology, proprietary technology, leading technology, second strategic alliance, technology platform

::: Sanochemia: European Marketing Authorisation for MRT Imaging Agent
MRT Imaging Agent, underlines Sanochemia, Sanochemia Pharmazeutika AG, European Marketing Authorisation, paramagnetic imaging agent, European DCP phase, year of the European launches, awarding of national marketing authorisations, marketing activities, marketing partners

::: AM-Pharma presents positive results of its Phase II clinical trial with Alkaline Phosphatase in Acute Kidney Injury at the ISICEM conference in Brussels
Alkaline Phosphatase results, bovine Alkaline Phosphatase, Alkaline Phosphatase intravenously, proprietary recombinant human Alkaline Phosphatase, Acute Kidney Injury trial, treatment of Acute Kidney Injury, Renal creatinine clearance, AKI patients, AM-Pharma presents positive results, first trial

::: 3SBio Announces Changes to its Board of Directors
director of 3SBio, visit 3SBio, independent director, non-executive director, China Southern Fund Management Company, Board of Directors, leading biotechnology company, company officer, predecessor company, Peiguo Cong